Spondylitis Association of America
    
 
Section Home
 
News Archive
 
Press Releases
 
Patients & Experts Available for Interview
 
Special Report:
TNF-a Inhibitors
Enbrel, Remicade
and Humira

Remicade Approved For Use In Treating
Juvenile Crohn's Disease

5/19/2006

Centocor has announced that the FDA approved their biologic medication, Remicade, for use in treating Crohn's Disease in children. According to their press release, this makes Remicade, "the first and only biologic therapy approved for the treatment of pediatric Crohn's disease, a debilitating condition that causes inflammation of the gastrointestinal (GI) tract, typically resulting in symptoms such as diarrhea, fever, abdominal pain, weight loss and, in some sufferers, delayed development and stunted growth."

The entire press release can be read by clicking here

As many people with spondylitis know, problems of the GI tract are not uncommon in ankylosing spondylitis and related diseases. The presence of Crohn's Disease or ulcerative colitis can sometimes assist a doctor in diagnosing a patient with AS when taking other symptoms into account: AS Diagnosis

The biologic medications currently being used to treat ankylosing spondylitis include Remicade, Enbrel and Humira. More information on these medications can be found in the AS Medications section:

AS Medications

And in our ongoing report on these biologics:

The Biologics: TNF-a Inhibitors


STAY INFORMED!

Stay up-to-date on all the latest news and information regarding AS and related diseases with our news magazine, Spondylitis Plus. Your subscription comes free with SAA membership, so click here to join today!




Join SAA   |    Educational Materials   |    Contact Us   |    Site Map   |    Privacy Statement
© 2008 Spondylitis Association of America, All Rights Reserved